Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.

Molecular bioSystems - 1 Apr 2012

Seyhan Attila A, Varadarajan Usha, Choe Sung, Liu Wei, Ryan Terence E

Abstract excerpt

Neratinib (HKI-272) is a small molecule tyrosine kinase inhibitor of the ErbB receptor family currently in Phase III clinical trials. Despite its efficacy, the mechanism of potential cellular resistance to neratinib and genes involved with it remains unknown. We have used a pool-based lentiviral genome-wide functional RNAi screen combined with a lethal dose of neratinib to discover chemoresistant interactions...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease
Share to Gene Regulatory Networks

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, Neoplasm

Share to Lentivirus

Share to Quinolines

Share to RNA Interference

Share to RNA, Small Interfering

Share to Transduction, Genetic

Source

Identifiers

PMID: 22446932
DOI: 10.1039/c2mb05512k

Genes

TFEC
CCNF
FOXP4
CLIC3
DDO
FXR1
GNA13
IGFBP1
OLFM2
PMEPA1
SOX5
UBL5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.PMID 22446932Read ↗

A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatmentsSemantic proximity Read ↗

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitorsSemantic proximity Read ↗

Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4Semantic proximity Read ↗

Functional Analysis of Non-Genetic Resistance to Platinum in Epithelial Ovarian Cancer Reveals a Role for the MBD3-NuRD Complex in Resistance DevelopmentSemantic proximity Read ↗

Peptidylarginine Deiminase 3 Modulates Response to Neratinib in HER2 Positive Breast CancerSemantic proximity Read ↗

Genome-wide profiling identifies the genetic dependencies of cell death following EGFR inhibitionSemantic proximity Read ↗

In Silico Transcriptome-based Screens Identify Epidermal Growth Factor Receptor Inhibitors as Therapeutics for Noise-induced Hearing LossSemantic proximity Read ↗

Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibitionSemantic proximity Read ↗

Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancerSemantic proximity Read ↗

Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.Semantic proximity Read ↗

ZNF300 promotes chemoresistance and aggressive behaviour in non‐small‐cell lung cancerSemantic proximity Read ↗

CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.